in vivo Studies Articles

Bio X Cell New Product Launch: RecombiMAb – Recombinant Antibodies

Recombinant antibodies for in vivo useWhat Are RecombiMAb™ Recombinant Antibodies?   Bio X Cell RecombiMAb™ monoclonal antibodies are recombinant antibodies with the exact same antigen-binding variable domains as the traditional antibodies that they are derived...

Macrophages weaken TLR9 agonist antitumor activity through interacting with the anti-PD-1 antibody Fc domain

A combination of TLR9 agonists and an anti-PD-1 antibody has been reported effective in immunocompetent mice. However, the role of innate immunity has not yet been explained. In a recent article published by the Cancers, by using Bio X Cell’s anti-mouse PD-1 in vivo...

Scientists identified TRAPPC4 as a crucial PD-L1 regulator

Tumour cells escape T cell-mediated immunosurveillance through the interaction between programmed death (PD-1) ligand 1 (PD-L1) on tumour cells and PD-1 on T cells. Strategies disturbing PD-1/PD-L1 have shown clinical advantages in various cancers. However, the...

LincRNA EPIC1 Mediates Immunotherapy Resistance

Bio X Cell has recently released a blog post talking about the role of LincRNA EPIC1 in cancer immunology.  Below are the highlights from the blog post:The ability of tumour cells to evade immune detection plays a critical role in tumour development. Although...